Filing Flows › DexCom (DXCM) › Capital expenditures
DexCom (DXCM) capital expenditures by quarter
DexCom's capital expenditures were $52.9M in Q3 2026 (third quarter 2026), -38% from Q2 2026. Over the last 7 quarters it ranged from $52.9M (Q3 2026) to $102M (Q4 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $52.9M | -38% | -34% |
| Q2 2026 | $84.7M | +11% | -10% |
| Q1 2026 | $76.6M | -25% | -12% |
| Q4 2025 | $102M | +27% | — |
| Q3 2025 | $80.5M | -14% | — |
| Q2 2025 | $94.1M | +8% | — |
| Q1 2025 | $87.0M | — | — |
Q3 2026 at a glance
DexCom, Q3 2026: revenue $1.3B (+11% year over year), operating margin 24.3%, net earnings $275M, operating cash flow $326M. The chart follows the revenue to costs, profit and cash.
Questions
What is DexCom's capital expenditures?
DexCom's capital expenditures were $52.9M in Q3 2026 (third quarter 2026), -38% from Q2 2026.
How has DexCom's capital expenditures changed?
Over the last 7 quarters it ranged from $52.9M (Q3 2026) to $102M (Q4 2025).